BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31283542)

  • 1. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
    Jian H; Han Y; Yu Y; Lu S
    Anticancer Drugs; 2019 Sep; 30(8):873-878. PubMed ID: 31283542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
    Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
    JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report.
    Sun M; Guo Y; Wang X; Sun C; Shao J; Xu Y; Qiu S; Ma K
    J Int Med Res; 2020 Oct; 48(10):300060520964700. PubMed ID: 33115309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
    Han C; Ding X; Li M; Luo N; Qi Y; Wang C
    J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
    Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
    Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
    Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
    Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
    Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
    Schuler M; Paz-Ares L; Sequist LV; Hirsh V; Lee KH; Wu YL; Lu S; Zhou C; Feng J; Ellis SH; Samuelsen CH; Tang W; Märten A; Ehrnrooth E; Park K; Yang JC
    Lung Cancer; 2019 Jul; 133():10-19. PubMed ID: 31200814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
    Abdallah SM; Hirsh V
    Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
    Halmos B; Tan EH; Soo RA; Cadranel J; Lee MK; Foucher P; Hsia TC; Hochmair M; Griesinger F; Hida T; Kim E; Melosky B; Märten A; Carcereny E
    Lung Cancer; 2019 Jan; 127():103-111. PubMed ID: 30642537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
    Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
    Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
    Vidal ÓJ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
    Levy B; Paz-Ares L; Bennouna J; Felip E; Abreu DR; Isla D; Barlesi F; Molinier O; Madelaine J; Audigier-Valette C; Kim SW; Kim HR; Ozguroglu M; Erman M; Badin FB; Mekhail TM; Scheff R; Chisamore MJ; Sadrolhefazi B; Riess JW
    Clin Lung Cancer; 2019 May; 20(3):e407-e412. PubMed ID: 30808583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
    van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
    J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population.
    Sutandyo N; Hanafi A; Jayusman M
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):562-567. PubMed ID: 31526459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.